Lu AA21004 News
Most Popular Lu AA21004 Story
Lundbeck turns in promising depression data
Lundbeck and its development partner Takeda have announced positive Phase II results for Lu AA21004, a treatment for depression. Study data showed significant improvements on the primary efficacy Read more...
Latest Headlines
- October 2, 2007
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
